Editor's Note Bariatric surgery programs nationwide have reported a 20-25% decline in surgical volumes over the past year amid the rising use of glucagon-like peptide-1 (GLP-1) medications for obesity, OR Management News reported Dec 2. Although the connection between the decline and the popularity of the drugs cannot be definitively…

Read More

Editor's Note Access to GLP-1 medications is improving as manufacturers, insurers, and policymakers address high demand, costs, and coverage challenges, Becker’s Hospital Review reported December 13. As detailed in the article, Eli Lilly’s partnership with telehealth company Ro now allows patients to obtain Zepbound prescriptions online and receive shipments directly…

Read More

Editor's Note Demand for skin removal surgeries has risen sharply in the US, fueled by the popularity of GLP-1 weight loss drugs like Ozempic and Wegovy, CNN reported December 9. The trend reflects a growing need for procedures that address loose, sagging skin following significant weight loss, particularly as the…

Read More

Editor's Note The US Food and Drug Administration (FDA) designated Cardinal health’s recall of certain lots of the Monoject U-100 1 mL Syringe Luer-Lock with Tip Cap Soft Pack a Class 1, the most severe recall category indicating serious risk of injury or death. The product is designed to administer…

Read More

Editor's Note Glucagon-like peptide-1 receptor agonists (GLP-1s) could reduce total knee arthroplasty (TKA) complications for non-diabetic patients with obesity, according to a November 13 Helio report on research presented at the American Association of Hip and Knee Surgeons Annual Meeting. In addition to reduced odds of 90-day medical complications, the…

Read More

Editor's Note The US Food and Drug Administration (FDA) has updated the labels of all treatments containing GLP-1 receptor agonists with a warning about warning about pulmonary aspiration during general anesthesia or deep sedation. Drugs and brand names listed in a November 8 report on the development from MedPage Today…

Read More

Editor's Note Joint guidance from key US medical associations advises that most patients on GLP-1 weight-loss medications, such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro), may safely continue these drugs before surgery, HealthDay News reported October 31. Concerns had emerged about potential risks associated with these medications due to their…

Read More

Editor's Note Combining newer weight loss drugs with bariatric surgery is the most cost-effective long-term strategy for treating obesity, according to research presented at the American College of Surgeons Clinical Congress 2024. Medical Xpress reported on the findings October 18. According to the article, researchers from Northwestern Medicine evaluated the…

Read More

Editor's Note Patients using GLP-1 receptor agonists (GLP-1 RAs) have a higher risk of food retention during esophagogastroduodenoscopy (EGD) when performed alone, but not when combined with a colonoscopy, according to a retrospective study from Cedars-Sinai Medical Center. MedPage Today reported the news October 1. The study included 70 patients…

Read More

Editor's Note Bariatric surgery significantly reduces the progression of chronic kidney disease (CKD) in patients with type 2 diabetes and obesity compared to those on GLP-1 diabetes medications, according to a study from Cleveland Clinic. Published in Annals of Surgery and detailed in a September 20 announcement from Cleveland Clinic,…

Read More